

Saturday, August 30, 2014

Room 01 (Conference Center, 1F, Main Hall)

8:10 - 16:00

**Special Session**

"Message from Fukushima"

8:10 - 8:55

**Special Lecture 02**Moderator: Keizo Sugimachi (*Onga Hospital*)

- SL2-1** **Scope for the future of Fukushima; resilience creation after the nuclear accident**  
Nagasaki University Shunichi Yamashita

9:00 - 9:50

**Special Lecture 03**

Anne Frank and Fukushima

Moderator: Tetsuichiro Muto (*Cancer Institute Hospital of JFCR*)

- SL3-1** **The Anne Frank House in Amsterdam as a Memorial Site: Five Decades of Active Learning Methodology in International Practice**  
*MA, Anne Frank House, Amsterdam, The Netherland* Jan Erik Dubbelman
- SL3-2** **History, memory and trauma: Holocaust survivor testimonies and the potential of oral history**  
*VU University Amsterdam, The Netherland* Dienke Hondius

10:00 - 12:00

**Special Session 01**

Nuclear Disaster and Health: Evidence from Fukushima

Commentators: Masafumi Abe (*Fukushima Medical University*)  
Hitoshi Ohto (*Fukushima Medical University*)

- SS2-1** **Measurement of internal radiation exposure of Fukushima residents after the Great East Japan Earthquake by Whole Body Counter**  
*Department of Radiation Health Management, Fukushima Medical University* Makoto Miyazaki
- SS2-2** **Measurement of Internal Exposure Doses with Meals by Duplicate Diet Method**  
*Department of Welfare, Fukushima College* Osamu Sato
- SS2-3** **Radioactive Substances in tap water**  
*Food Safety & Environmental Hygiene Division, Social Health & Welfare Department, Fukushima Prefecture* Ryo Atsumi
- SS2-4** **Radiation exposure and thyroid ultrasound examination from the data of the Fukushima Health Management Survey**  
*Dept. of Thyroid and Endocrinology, Fukushima Medical University* Shinichi Suzuki
- SS2-5** **Pregnancy and birth survey in Fukushima after radiation disaster**  
*Department of Obstetrics and Gynecology, School of Medicine, Fukushima Medical University* Keiya Fujimori
- SS2-6** **Changes in health status among residents after the Great East Japan Earthquake: the Fukushima Health Management Survey**  
*Department of Epidemiology, School of Medicine, Fukushima Medical University* Tetsuya Ohira

**SS2-7 Mental health problems of the evacuees disclosed by Fukushima Health Management Survey***Department of Neuropsychiatry, Fukushima Medical University*

Hirooki Yabe

13:30 - 16:00

**Special Session 03**

Movie : Hameln (Japanese Only)

Room 02 (Conference Center, 3F, 301+302)

8:00 - 10:00

**Organ Specific Symposium 17**Up-to-Date Breast Cancer Treatment  
-New Strategies in the Treatment of HER2 Positive Diseases-**Moderators:** Masakazu Toi (*Breast Surgery, Kyoto University Hospital*)Tohru Ohtake (*Department of Regulatory Surgery, Fukushima Medical University*)**OS17-1 Updates on Development of anti-HER2 treatment***Stanford Cancer Institute, Stanford University School of Medicine, U.S.A.*

Mark D. Pegram

**OS17-2 New development of treatment for HER2-positive metastatic breast cancer***Breast Medical Oncology, The Cancer Institute Hospital*

Yoshinori Ito

**OS17-3 Novel treatment strategies for HER2-positive breast cancers***Division of Breast and Endocrine, Department of Surgery, Hyogo College Of Medicine*

Yasuo Miyoshi

**OS17-4 Current status and future perspective in primary systemic therapy for HER2-positive breast cancer patients***Surgery, Breast Oncology, Osaka Medical Center, National Hospital Organization*

Norikazu Masuda

**OS17-5 New treatment strategy for HER2 positive breast cancer***Aichi Cancer Center Hospital and Research Institute*

Hiroji Iwata

**OS17-6 Treatment strategy for Luminal-HER2 and HER2-enriched breast cancer based on biological characteristics***Division of Breast Oncology, National Hospital Organization Kyushu Cancer Center*

Shinji Ohno

Room 03 (Conference Center, 3F, 303+304)

8:00 - 10:00

**Symposium 13**

The Current Situations and Issues of Clinical Researches in Japan for Recovering of Trust

**Moderators:** Yasuhiro Fujiwara (*Strategic and Planning Bureau, National Cancer Center*)Kazuhiro Yoshida (*Department of Surgical Oncology, Gifu University*)**S13-1 New Framework for Promoting Medical Research and Development**

Office of Healthcare Policy, Cabinet Secretariat

**S13-2 Measures taken by Ministry of Health, Labour and Welfare - Revision of the Ethical Guidelines for Clinical Studies and the situation revolving around clinical study***Health Policy Bureau Research and Development Division, Office of Clinical Trial Promotion, Ministry of Health, Labour and Welfare*

Yuta Ogawa

**S13-3 Legal Regulation for the Clinical Research in the Context of Global Trends***Law School, Keio University*

Tetsu Isobe

**S13-4 Changing policies on human research protections in Japan**

*Office for Promoting Medical Research, Showa University*

Shimon Tashiro

Room 03 (Conference Center, 3F, 303+304)

10:00 - 12:00

**Plenary Session**

**Moderator:** Seiichiro Ozono (*Urology, Hamamatsu University School of Medicine*)

**PS-1 Upper urinary tract recurrence following intravesical BCG therapy for non-muscle invasive bladder cancer: a multi-institutional retrospective study**

*Department of Urology, Hospital, Sapporo Medical University*

Naotaka Nishiyama

**PS-2 Male infertility treatment after cancer**

*Urology, Graduate School of Medicine, Yamaguchi University*

Koji Shiraiishi

**Moderator:** Eigo Otsuji (*Digestive Surgery, Graduate School of Medical Science, Kyoto Prefectural University of Medicine*)

**PS-3 Current status and future perspective of sentinel node navigation surgery in gastric cancer**

*Department of Surgery, School of Medicine, Keio University*

Hiroya Takeuchi

**PS-4 A randomized phase III trial of mFOLFOX6+bevacizumab vs. FOLFIRI+bevacizumab for metastatic colorectal cancer: WJOG4407G**

*Department of Medical Oncology, Nara Hospital Kinki University*

Takao Tamura

**Moderator:** Hiroyuki Kuwano (*General Surgical Science, Graduate School of Medicine, Gunma University*)

**PS-5 Improved Postoperative Prognosis of Pancreatic Cancer with Para-aortic Lymph Node Metastasis: A Multicenter Study on 822 Patients**

*Surgery, Nara Medical University*

Masayuki Sho

**PS-6 A randomized phase III study of cisplatin etoposide and irinotecan versus topotecan as second-line chemotherapy in patients with sensitive relapsed small-cell lung cancer : JCOG0605**

*National Cancer Center Hospital*

Noboru Yamamoto

**Moderator:** Hidetaka Katabuchi (*Department of Obstetrics and Gynecology, Faculty of Life Sciences, Kumamoto University*)

**PS-7 Efficacy and safety of anti-PD-1 antibody (Nivolumab : BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer**

*Obstetrics and Gynecology, Hospital, Kyoto University*

Junzo Hamanishi

**Moderator:** Takafumi Ueda (*Dept of Orthopaedic Surgery, Osaka Medical Center, National Hospital Organization*)

**PS-8 Circulating miR-206 as a novel prognostic biomarker for rhabdomyosarcoma**

*Department of Pediatrics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine*

Mitsuru Miyachi

Room 06 (Conference Center, 3F, 315)

8:00 - 10:00

**International Symposium 06 (Princess Takamatsu Cancer Research Fund Sponsored)****The Future of Cancer Therapy  
-Cancer Immunotherapy by Checkpoint Blockade-**

**Moderators:** **Yutaka Kawakami** (*Institute for Advanced Medical Research Division of Cellular Signaling, School of Medicine, Keio University*)  
**Hiroshi Shiku** (*Department of Immuno-Gene Therapy, Mie University Graduate School of Medicine*)

**TIS6-1 A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application**  
*Department of Immunology and Genomic Medicine, Graduate School of Medicine, Kyoto University* Tasuku Honjo

**TIS6-2 Cancer Immunotherapy by Checkpoint Blockade**  
*Department of Medical and Molecular Pharmacology;  
 Department of Medicine, Division of Hematology / Oncology,  
 University of California Los Angeles (UCLA),  
 and the Jonsson Comprehensive Cancer Center at UCLA, U.S.A.* Antoni Ribas

**TIS6-3 Blocking the PD-1 / PD-L1 Interaction to Treat Cancer**  
*Immunology, Oncology and Urology, Johns Hopkins Kimmel Cancer Center, U.S.A.* Charles G. Drake

**TIS6-4 Checkpoint blockade-based combination therapies against cancer**  
*Department of Immunology, Graduate School of Medicine, Yamaguchi University* Koji Tamada

Room 07 (Conference Center, 4F, 413)

8:00 - 10:00

**Symposium 14****Cancer Education at School**

**Moderators:** **Keiichi Nakagawa** (*Department of Radiology, Hospital, The University of Tokyo*)  
**Izumi Nakamura** (*Department of Regulatory Surgery, Fukushima Medical University*)

**S14-1 Outlook and practice of cancer education**  
*Radiology, Hospital, The University of Tokyo* Keiichi Nakagawa

**S14-2 Efforts report - from 2010 - the cancer education cancer patients tell**  
*Nonprofit Organization Gan Support Kagoshima* Aya Miyoshi

**S14-3 The measures of cancer education in Kanagawa Prefecture**  
*Cancer Division, Kanagawa Prefectural Government* Yoko Nakazawa

**S14-4 JCS efforts for cancer class**  
*Project Proposal, Japan Cancer Society* Rie Anami

**S14-5 A Prospect of "Cancer Education" in Japan**  
*Director, School Health Education Division,  
 Ministry of Education, Culture, Sports, Science and Technology* Masahiro Oji

Room 10 (Conference Center, 4F, 418)

8:00 - 8:30

**Keynote Lecture 08**

**Moderator:** **Koichi Hagiwara** (*Department of Respiratory Medicine, Saitama Medical University*)

**KL8-1 Secretoglobin (SCGB) 3A2 is a novel anti-tumor agent**  
*Endocrinology Section, Laboratory of Metabolism, National Cancer Institute, U.S.A.* Shioko Kimura

Room 10 (Conference Center, 4F, 418)

8:30 - 9:20

**International Session 2****Anti Cancer Agent****Moderators:** Osamu Ogawa (*Department of Urology, Faculty of Medicine, Kyoto University*)Mitsuo Shimada (*Department of Surgery, Graduate School, The University of Tokushima*)**ISO2-1 ER alpha regulates Epithelial-mesenchymal transition in breast cancers through suppressing Bmi1 expression***The Breast Center, The Affiliated Cancer Hospital of Shantou University Medical College, China*

Guo-jun Zhang

**ISO2-2 Monocyte Chemoattractant Protein-1 Modulates Invasion and Apoptosis of PC-3M Prostate Cancer Cells Via Regulating Expression of VEGF, MMP9 and Caspase-3***Urology, FAW General Hospital, China*

Chaoling Shi

**ISO2-3 Results of the first-in-human phase I trial assessing the oral selective c-Met inhibitor MSC2156119J (EMD 1214063) in patients with advanced solid tumors***Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), MD Anderson Cancer Center, U.S.A.*

Gerald S. Falchook

**ISO2-4 Ubiquitin Ligase Inhibitor is an Effective Combination Therapy with Radiation in Hypoxic Colorectal Cancer Cells***Radiation Oncology, Graduate School, Gunma University*

Navchaa Gombodorj

**ISO2-5 A novel anti-cancer agent of DNA-alkylating Pyrrole-Imidazole polyamide conjugate targeting KRAS Codon 12 Mutant DNA***Cancer Genetics, Chiba Cancer Center*

Hiroki Nagase

**ISO2-6 Implication of IRSp53 in cell proliferation by interaction with p107 via NPY motif***Molecular Medicine Cell Biology Lab, Graduate School of Biological Sciences, NAIST, Japan*

Fatemeh Safari

Room 12 (Conference Center, 5F, 501)

8:00 - 10:00

**Organ Specific Symposium 18****Up-to-Date Liver Cancer Treatment****Moderators:** Go Wakabayashi (*Surgery, Iwate Medical University*)Hiroaki Nagano (*Department of Surgery and Transplant Medicine, Graduate School, Osaka University*)**OS18-1 Hepatectomy for colorectal liver metastases after chemotherapy***Department of Gastroenterological Surgery, Aichi Cancer Center Hospital*

Yoshiki Senda

**OS18-2 Possible prevention of the development and recurrence of hepatocellular carcinoma by antiviral therapy for persistent hepatitis B or C viral infection***Department of Hepatology, Graduate School of Medicine, Osaka City University*

Norifumi Kawada

**OS18-3 Comparison of the efficacy of sorafenib and hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma***Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University*

Makoto Chuma

**OS18-4 The goal of multidisciplinary treatment for advanced hepatocellular carcinoma***Department of Surgery, Graduate School of Medicine, Kyoto University*

Etsuro Hatano

**OS18-5 Current status and future of liver transplantation***Division of Transplant Surgery, Department of Surgery, School of Medicine, Shinshu University*

Toshihiko Ikegami

**OS18-6 The 3rd version of Clinical Practice Guidelines for Hepatocellular Carcinoma: revision procedures and current problems***Hepato-Biliary-Pancreatic Surgery Division, Graduate School of Medicine, The University of Tokyo*

Kiyoshi Hasegawa

Room 13 (Conference Center, 5F, 502)

8:00 - 10:20

**Organ Specific Symposium 19****Up-to-Date Head and Neck Cancer Treatment****Moderators:** Tadaaki Kirita (*Department of Oral and Maxillofacial Surgery, Nara Medical University*)Kenichi Nibu (*Department of Otolaryngology-Head and Neck Surgery, Graduate School of Medicine, Kobe University*)**OS19-1 Treatment strategy for oral cancer, up to date***Department of Oral and Maxillofacial Surgery, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University*

Ken Omura

**OS19-2 Functional unit reconstruction after oral oncologic surgery***Department of Stomatology and Maxillofacial, Graduate School of Medicine, Gunma University*

Satoshi Yokoo

**OS19-3 Nasopharyngeal carcinoma -Treatment concept according to EBV status-***Otolaryngology-Head and Neck Surgery, Kanazawa University*

Tomokazu Yoshizaki

**OS19-4 Human Papillomavirus and Cystic Node Metastasis in Oropharyngeal Cancer and Cancer of Unknown Primary***Department of Otorhinolaryngology-Head and Neck Surgery, Graduate School of Medicine, Osaka University*

Hidenori Inohara

**OS19-5 Flexible endoscopic transoral surgery using a curved distending laryngoscope in patients with early-stage hypopharyngeal cancer***Otolaryngology, Tokyo Medical and Dental University*

Taro Sugimoto

**OS19-6 Molecular-targeted agent***School of Medicine, Department of Oto-Rhino-Laryngology, The Jikei University*

Susumu Okano

Room 14 (Conference Center, 5F, 503)

8:00 - 10:00

**Organ Specific Symposium 20****Up-to-Date Endometrial Cancer Treatment****Moderators:** Tsutomu Tabata (*Obstetrics and Gynecology, Faculty of Medicine, Mie University*)Nobuhiro Takeshima (*Gynecology, The Cancer Institute Hospital*)**OS20-1 Limited resection for endometrial cancer***Department of Obstetrics and Gynecology, Mie University Hospital*

Takashi Motohashi

**OS20-2 Tailoring lymphadenectomy in the surgical management of endometrial cancer***Gynecology, Hokkaido University Hospital*

Hidemichi Watari

**OS20-3 How to safely perform a laparoscopic surgery for endometrial cancer***Kurashiki Medical Center*

Hiroyuki Kanao

**OS20-4 Sentinel Lymph Node in Endometrial Cancer***Obstetrics and Gynecology, Osaka Medical College*

Yoshito Terai

**OS20-5 Adjuvant treatment for uterine corpus cancer***Obstetrics & Gynecology, Faculty of Medicine, Tottori University*

Muneaki Shimada

**OS20-6 Platinum-free interval (PFI) in second-line chemotherapy for recurrent endometrial cancer***The Cancer Institute Hospital*

Maki Matoda